Intacs®
Intraocular Rings and Keratoconus
Intacs is a corneal prescription ring insert used for
patients with low myopia and more recently, keratoconus.
Placement of Intacs prescription inserts is entirely
reversible. Thus, patients who elect to have Intacs
placed in their eyes are not “locked in” to the procedure
forever, as are patients who undergo certain other
refractive procedures such as LASIK, where corneal tissue is
actually removed by the excimer
laser.
Vision correction with Intacs entails implanting the
micro-thin intracorneal rings into the cornea by a trained
eye surgeon. Intacs produce a reshaping of the curvature of
the cornea, reliably reducing low degrees of myopia
(nearsightedness). Intacs cannot be felt by the patient,
require no maintenance, and are probably less visible than a
contact lens to the naked eye. Intacs have been studied for
about 15 years and are FDA approved. The primary drawback at
the present time is two-fold: 1) Intacs are only available
in the U.S. for low degrees of myopia (-1.00 to –3.00 diopters) and 2) this procedure has never gained widespread
public acceptance, almost certainly because it has been
greatly overshadowed by LASIK, thus making access difficult.
As such, few eye surgeons are implanting Intacs at this
time.

Intacs are prescription inserts, which can be removed or
replaced if one’s vision
needs change or there is any
dissatisfaction with the corneal ring inserts. In the U.S.
clinical trials, all of the very few people who had Intacs
removed could subsequently be corrected to 20/20 or better
vision.
Indications for Intacs
Intacs inserts is intended for the reduction or
elimination of mild myopia of –1.0 to –3.0 diopters in
patients who meet the following additional criteria:
- 21 years of age or greater
- documented stability of refraction as demonstrated
by a change of refraction less than or equal to 0.50
diopters for at least 12 months prior to the
preoperative examination
- the astigmatic component of the refraction is +1.0
diopters or less
Visual Results
Amazingly, 53% of patients see 20/16 or better as a
result of their primary procedure and 34% see 20/20 or
better the day after the procedure! One month after surgery
79% of patients see 20/25 or better and by one year 87% of
patients see 20/25 or better. Fully 97% of patients are
20/40 or better one year following surgery (20/40 is a
"benchmark" of visual acuity as this level of vision allows
unrestricted passage of a driver's license test in most
states)[i].
Furthermore, placement of Intacs maintains the “normal”
positive asphericity (shape) of the cornea whereas
excimer
laser procedures such as LASIK and
PRK frequently produce
oblate corneas. The latter condition may result in reduced
contrast sensitivity. Visual correction with Intacs is also
rapid and stable. Eighty percent of patients have 20/40 or
better vision the day after surgery. A year after surgery,
over 50% of patients see 20/16 or better as a result of
their first procedure, i.e., without enhancements.
The Procedure
Intacs corneal ring prescription inserts are placed
within the substance of the cornea under topically applied
(eye drop) anesthesia. No needles or injections are
required. Some patients may experience mild and temporary
discomfort during the procedure. The
surgeon makes a tiny
incision in the top of the cornea, creates a 180 degree
tunnel in which to place the first prescription insert, and
then places the Intacs ring in the corneal tunnel. A similar
procedure is used to place the second Intacs ring.
Two Intacs inserts are placed in each eye, each of which
approximates a near half-circle. The tiny incision through
which the Intacs is placed is usually closed with a single
stitch that can be removed within a few days or weeks. The
entire procedure usually takes about 15 to 20 minutes per
eye.
What to Expect After Surgery
The day of surgery, the operated eye may feel somewhat
scratchy and vision
may be blurred. Do not be alarmed. Any
discomfort will usually be relieved by anti-inflammatory eye
drop medications. You will be instructed to use both
antibiotic and steroid eye drops, generally for about two
weeks following surgery. On the first postoperative day,
vision is usually good enough to drive a car, i.e., 20/40 or
better, but may be reduced if the eye remains dry or an
abrasion of the corneal surface has occurred.
You will not be able to feel your Intacs inserts,
however, you may feel the tiny incision and or stitch as the
incision heals. This will usually resolve within a couple of
days. If a suture was placed, your
surgeon will probably
remove it in about 2 to 4 weeks. With Intacs prescription
inserts, you may expect your vision to recover very quickly
and to continue to improve for up to 6 to 12 months.
Intacs® Prescription Inserts for Keratoconus
Defining Keratoconus
Keratoconus is a corneal degenerative disorder, in which
the cornea becomes progressively thin and steep, resulting
in irregular astigmatism. The front of the eye, therefore,
is "bulging" and irregular in topography. The presenting
complaint is poor vision
and inability to correct vision
well with glasses, and sometimes,
contact lenses. Only about
10% of patients have a positive family history of
keratoconus. However, 90% of cases are bilateral suggesting
a possible genetic basis. The condition usually presents in
the teenage years and has a variable progression.
Diagnosis of Keratoconus
Keratoconus may be difficult to diagnose in the early
stages. One of the most reliable methods of detection,
however, is corneal topography. This diagnostic procedure is
routinely completed prior to refractive surgery. If the
patient is found to have keratoconus, refractive surgery,
such as LASIK, is generally contraindicated as the outcome
of such surgery may be unpredictable. In the more advanced
stages of keratoconus, the diagnosis may be made with a
slit-lamp microscope by observing the grossly distorted and
thinned cornea.

Management of Keratoconus
In the early stages of keratoconus, most patients achieve
good vision with glasses. As the condition progresses, many
patients require rigid gas permeable
contacts for
successful correction. In advanced stages, the patient
may develop the condition known as acute corneal hydrops,
which represents sudden development of corneal edema
(swelling) due to rupture of Descemet's membrane, a membrane
near the posterior (deep side) of the cornea. The acute
episode often resolves but results in corneal scarring and,
perhaps, permanent visual reduction. At this stage, the
patient will most likely be referred to a corneal specialist
in consideration of corneal transplantation.
Intacs for Keratoconus
When patients fail to achieve adequate vision with
glasses or contacts, then Intacs prescription inserts
may be placed in an attempt to improve visual acuity and
delay or prevent the need for corneal transplantation.
The U.S. FDA gave a “humanitarian device approval” for the
insertion of Intacs for this purpose on July 26, 2004[ii]i].
The Intacs prescription insert has been shown to help
flatten the bulging cornea in some patients with
keratoconus, thereby improving visual acuity and postponing
the need for corneal transplant. The FDA states that
Intacs inserts should not be used in keratoconus patients
who:
- can achieve functional vision on a daily basis using
eyewear
- are younger than 21 years of age
- do not have clear central corneas
- have a corneal thickness less than 450 microns at
the proposed incision site
In what is probably the largest study published on the
use of Intacs prescription inserts for the treatment of
keratoconus, seventy-four eyes of 50 subjects were evaluated
following placement of Intacs[iiiii].
Patient ages ranged from 20 to 73 years. In most
cases, a thicker Intacs ring segment was placed inferiorly
(lower) in the cornea along with a thinner Intacs segment
superiorly (higher). This is because, in most cases,
the “cone”, or the bulging aspect of the cornea, is located
inferiorly.
The mean (average) preoperative uncorrected visual acuity
was about 20/250, which improved to a postoperative mean of
about 20/80. That is, on average, patients gained
about four lines of uncorrected vision on the standard
Snellen eye chart that is used in most doctors’ offices.
In patients with keratoconus and corneal scarring, the mean
pre-operative best-corrected visual acuity was about 20/150,
which improved to about 20/65 postoperatively.
This indicates that this group improved about five lines on
the eye chart. The study group concluded that, “Intacs
implantation can improve both uncorrected and best
spectacle-corrected visual acuity and can reduce irregular
astigmatism in corneas with and without corneal scarring.”
Conclusion
Intacs prescription inserts have shown excellent results
in the treatment of low degrees of myopia. However, I
believe that their use never really took a foothold because
the company (Addition Technology, Inc.) simply could not
afford to compete with the national and international
marketing efforts by manufacturers of excimer lasers for
LASIK as well as physicians practices for LASIK. Even
though many EyeMDs initially trained to provide Intacs
inserts, relatively few ever surgically implanted them.
The technology is good and it is fully reversible for the
relatively few individuals who choose this technology as a
refractive procedure.
Today, I believe the main use of f Intacs prescription
inserts is for keratoconus patients who are unable to
achieve the vision they desire through glasses or contact
lenses and who would otherwise be left only with the
therapeutic option of corneal transplantation. In this
situation, a substantial number of patients might benefit
from placement of Intacs prescription inserts.
To find an EyeMD who implants Intacs prescription
inserts, visit Addition Technology’s website,
www.getintacs.com.
[i]
FDA Talk Paper. Food and Drug Administration. FDA
Approves Eye Implant to Correct Mild
Nearsightedness”. April 9, 1999, available at:
http://www.fda.gov/bbs/topics/ANSWERS/ANS00948.html
[ii]
Intacs Prescription Inserts for Keratoconus –
H04002. New Humanitarian Device Approval. U.S. Food
and Drug Administration. Available at:
http://www.fda.gov/cdrh/mda/docs/h040002.html
[iii]
Boxer-Wachler, BS, et al.
Ophthalmology. 2003 May; 110 (5); 1031-1040.
|